Prof. dr. Timothy Radstake

Prof. dr. Timothy Radstake

External Advisory Board

  • Director of Infection and Immunity Focis Center of Excellence, Utrecht Medical Center
  • Chair-elect EULAR Standing Committee on Investigative Rheumatology
  • Director European Society of Preventative Medicine (www.ESPREVMED.org)
  • Vice-Chair European Association of Systems Medicine (www.EASYM.EU)
  • GSK Immunology Catalyst PI

 

Professor Radstake MD, Ph.D. attended medical school at the Radboud University in Nijmegen the Netherlands where he graduated in 2000. He next performed his PhD on the genetic factors that determine the susceptibility to Rheumatoid arthritis and the role of dendritic cells in this conditions that he finished in 2003 under the supervision of Professors van Riel and van den Berg.

 
Soon after that he started his own research line on translational rheumatology with the ultimate aim to translate clinical problems to novel therapeutic targets. Although starting his research in rheumatoid arthritis, over the years his group investigated a broader spectrum of rheumatic conditions including psoriatic arthritis and systemic sclerosis. From 2007 – 2008 prof. Radstake did a post-doctoral fellowship on the department of rheumatology at the Boston University School of Medicine (prof. R. Lafyatis) where he held a chair until 2014.
 
From March 2012 he holds the chair on translational immunology at the university medical Center Utrecht were his research team, comprising roughly 40 fte, focuses on a systems medicine approach with the ultimate goal to achieve personalized health care on the basis of molecular taxonomy rather that clinical diagnosis. For this program he is involved in multiple efforts of the European Union with the aim to push the Systems Medicine forward in medicine in general. A side to his clinical work and role as director of the Utrecht Infection & Immunity FOCIS center of excellence, he is current involved as an entrepreneur in multiple projects to bring potential therapeutic targets to the market, anti-CXCL4 as a novel therapeutic entry-point for scleroderma being the most progressed.


 

© 2018 COSMIC. All Rights Reserved.

Please publish modules in offcanvas position.